Study of Therapy With TransMID™ Compared to Best Standard of Care in Patients With Glioblastoma Multiforme

Stopped This study has been withdrawn because the drug would not meet trial criteria for efficacy

Conditions

• Glioblastoma Multiforme

Interventions

• DRUG: TransMID™

Sponsor

Xenova Biomedix